IQVIA Holdings Inc. (NYSE:IQV) Stake Lessened by Primecap Management Co. CA

Primecap Management Co. CA trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 294,989 shares of the medical research company’s stock after selling 30,967 shares during the period. Primecap Management Co. CA owned about 0.16% of IQVIA worth $57,968,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of IQV. Synergy Asset Management LLC purchased a new stake in shares of IQVIA during the fourth quarter worth $33,000. Avior Wealth Management LLC raised its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. raised its holdings in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares in the last quarter. Meeder Asset Management Inc. raised its holdings in shares of IQVIA by 353.7% during the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock worth $58,000 after acquiring an additional 191 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 1.9 %

Shares of IQV opened at $188.45 on Wednesday. The stock has a market cap of $33.23 billion, a price-to-earnings ratio of 25.13, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $256.34. The company has a 50-day moving average price of $196.06 and a two-hundred day moving average price of $209.52.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

IQV has been the topic of several analyst reports. Morgan Stanley increased their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Stifel Nicolaus lowered their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th. Finally, UBS Group lowered their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.